Predictive Oncology (NASDAQ:POAI) Share Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:POAI) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $6.24 and traded as high as $7.40. Predictive Oncology shares last traded at $6.43, with a volume of 432,645 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on POAI. Wall Street Zen cut Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Predictive Oncology in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Predictive Oncology Trading Down 9.2%

The stock has a market cap of $21.82 million, a price-to-earnings ratio of -0.48 and a beta of 1.35. The company has a 50 day simple moving average of $6.24 and a 200-day simple moving average of $10.19.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings data on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative return on equity of 732.73% and a negative net margin of 5,065.23%. Equities analysts forecast that Predictive Oncology Inc. will post -2.08 earnings per share for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.